Gilead Sciences, Inc. (GILD)
169.05
+2.52
(+1.51%)
USD |
NASDAQ |
Nov 20, 10:00
Gilead Sciences Cash from Operations (Quarterly) : 5.035B for Sept. 30, 2026
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 5.035B |
| June 30, 2026 | 3.573B |
| March 31, 2026 | 2.544B |
| December 31, 2025 | 3.327B |
| September 30, 2025 | 4.108B |
| June 30, 2025 | 827.00M |
| March 31, 2025 | 1.757B |
| December 31, 2024 | 2.975B |
| September 30, 2024 | 4.309B |
| June 30, 2024 | 1.325B |
| March 31, 2024 | 2.219B |
| December 31, 2023 | 2.169B |
| September 30, 2023 | 1.755B |
| June 30, 2023 | 2.337B |
| March 31, 2023 | 1.745B |
| December 31, 2022 | 2.567B |
| September 30, 2022 | 2.863B |
| June 30, 2022 | 1.802B |
| March 31, 2022 | 1.84B |
| December 31, 2021 | 3.205B |
| September 30, 2021 | 3.253B |
| June 30, 2021 | 2.316B |
| March 31, 2021 | 2.61B |
| December 31, 2020 | 1.916B |
| September 30, 2020 | 2.25B |
| Date | Value |
|---|---|
| June 30, 2020 | 2.566B |
| March 31, 2020 | 1.436B |
| December 31, 2019 | 2.58B |
| September 30, 2019 | 2.899B |
| June 30, 2019 | 2.221B |
| March 31, 2019 | 1.444B |
| December 31, 2018 | 2.345B |
| September 30, 2018 | 2.212B |
| June 30, 2018 | 1.573B |
| March 31, 2018 | 2.27B |
| December 31, 2017 | 2.753B |
| September 30, 2017 | 2.694B |
| June 30, 2017 | 3.526B |
| March 31, 2017 | 2.925B |
| December 31, 2016 | 3.864B |
| September 30, 2016 | 4.33B |
| June 30, 2016 | 4.723B |
| March 31, 2016 | 4.13B |
| December 31, 2015 | 4.874B |
| September 30, 2015 | 4.096B |
| June 30, 2015 | 5.658B |
| March 31, 2015 | 5.701B |
| December 31, 2014 | 3.021B |
| September 30, 2014 | 4.044B |
| June 30, 2014 | 4.185B |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Regeneron Pharmaceuticals, Inc. | 1.783B |
| AbbVie, Inc. | 7.606B |
| Biogen, Inc. | 640.80M |
| Vertex Pharmaceuticals, Inc. | 643.10M |
| Amgen, Inc. | 4.241B |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -244.00M |
| Cash from Financing (Quarterly) | -1.528B |
| Free Cash Flow | 13.78B |
| Free Cash Flow Per Share (Quarterly) | 3.835 |
| Free Cash Flow to Equity (Quarterly) | 4.813B |
| Free Cash Flow to Firm (Quarterly) | 5.011B |
| Free Cash Flow Yield | 6.57% |